Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2+ Early or Locally Advanced Breast Cancer
Interventions: DRUG: pyrotinib + trastuzumab + nab-paclitaxel|DRUG: pertuzumab + trastuzumab + nab-paclitaxel
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University